"Although we only began selling Tri-Xanthin(TM) in the fourth quarter last year, we've already begun to see a surge in demand," said Joe Schortz, CEO of QBI. "Sales have been rapidly exceeding our sales forecast. Now, with the most recent order placed by a national retail chain, we're quite confident that we have a winning product on our hands that offers a unique alternative to weight loss products available today."

Tri-Xanthin(TM) has the ability to boost the body's natural fat burning process by delivering the exact amount of its three key components derived from standardized extracts of green tea, cocoa beans and the mate leaf. Ephedra was the most popular non-prescription ingredient for weight loss supplements and food products until it was banned last December, creating a considerable demand for safe ephedra-free alternatives. Tri-Xanthin(TM) offers similar weight loss properties of ephedra but without the adverse side effects.

"We see a tremendous market opportunity for this product," said Allan Himmelstein, President of QBI. "The demand for weight loss products is growing every day. Having a safe and efficacious product like Tri-Xanthin(TM) can easily translate into increased sales for us as major distributors and retailers begin stocking their shelves to meet the growing demand. We're excited about prospects for Tri-Xanthin(TM)."

About Health Sciences Group, Inc.

Health Sciences Group, Inc., is an integrated provider of innovative products and services in the nutraceutical, pharmaceutical, and cosmeceutical industries offering value-added ingredients, bioactive formulations, and proprietary technologies used in nutritional supplements, functional foods and beverages, and skin care products. Its largest division, Quality Botanical Ingredients, Inc. (QBI), processes more than 500 herbs, dried fruits and vegetables, and nutraceuticals using cryogenic (cold) processing at its New Jersey facility. Its XCEL Healthcare division is a fully licensed, specialty compounding pharmacy delivering full service pharmacology solutions to customers with chronic ailments that require long-term therapy; and its BioSelect Innovations division develops and sells innovative, science-based products based on proprietary technologies in the areas of topical/transdermal drug delivery, cosmeceuticals, and integrative medicine to a global network of customers who manufacture and distribute compounded pharmaceuticals, functional foods, skin care products and cosmetics.